Marwah Medicine

Medical

White Coat Hypertension vs Masked Hypertension

One causes over diagnosis and other one causes under diagnosis of hypertension. Learn the nuances of difference between both of them in next 1 minute of careful reading. Reading improves skill set. Watching reels decreases concentration span and students are not able to answer in real exam scenarios. Feature White Coat Hypertension Masked Hypertension Clinic BP High Normal Home/Ambulatory BP Normal High Cause Anxiety or stress during medical visits Blood pressure elevated during daily life but normal in clinic Risk of missed diagnosis May lead to overdiagnosis May lead to underdiagnosis Cardiovascular risk Lower than sustained hypertension but higher than normotension Similar to sustained hypertension; significant CV risk Example Clinic 150/95 mmHg Home 120/75 mmHg Clinic 125/80 mmHg Home 145/90 mmHg Diagnosis HBPM or 24-hour ABPM HBPM or 24-hour ABPM Management Lifestyle measures and follow-up; medication only if persistent hypertension develops or high risk Treat as true hypertension with lifestyle modification and antihypertensive therapy when indicated Easy Memory Hack White Coat: High blood pressure only when the doctor is watching. Masked: Hypertension is hidden in the clinic but present in everyday life

Medical

First Targeted Drug for Hepatitis D Every NEET PG Aspirant Must Know

Why is Hepatitis D Important? Hepatitis D virus (HDV) leads to faster progression of chronic viral hepatitis and can even lead to Fulminant hepatic failure.  It cannot survive on its own because it is a defective RNA virus that requires the HBsAg (Hepatitis B surface antigen) of Hepatitis B virus to enter hepatocytes and replicate. Golden Rule: No Hepatitis B = No Hepatitis D Patients with HDV progress much faster to: Cirrhosis Liver failure Hepatocellular carcinoma (HCC) Introducing Hepcludex (Bulevirtide) Bulevirtide (Brand: Hepcludex) is the first approved drug specifically designed for chronic Hepatitis D infection.   Mechanism of Action HDV enters hepatocytes by binding to the NTCP receptor (Sodium Taurocholate Cotransporting Polypeptide) present on liver cells. Bulevirtide blocks the NTCP receptor, thereby preventing: Entry of HDV Entry of HBV Infection of new hepatocytes   Easy Mnemonic Bulevirtide = BLOCKS the Liver Entry of Hepatitis B and Hepatitis D viruss   Indications Approved for: Chronic Hepatitis D Patients with compensated liver disease Usually given along with suppression of HBV replication using nucleos(t)ide analogues when indicated. Route Subcutaneous injection Once daily   Major Side Effects Common adverse effects include: Injection site reactions Elevated bile acids (expected because NTCP transports bile acids) Headache Fatigue Nausea   Why is This Drug Unique? Unlike conventional antivirals that inhibit viral replication, Bulevirtide prevents viral entry into liver cells. It is therefore called an entry inhibitor.   Previous Standard Therapy Earlier treatment relied mainly on: Pegylated Interferon-α Limitations: Low response rates Significant adverse effects Poor tolerability Bulevirtide has provided a major advance in the management of chronic HDV.   NEET PG MCQ A patient with chronic Hepatitis D is started on Hepcludex. Which of the following best describes its mechanism of action? Inhibits HBV DNA polymerase Inhibits viral RNA polymerase Blocks NTCP receptor-mediated viral entry into hepatocytes Inhibits viral protease Answer: C Explanation: Bulevirtide is the first HDV entry inhibitor. It blocks the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocytes, preventing HBV and HDV entry into liver cells.   Take-Home Message If you remember just one line for your exam: Hepcludex (Bulevirtide) = NTCP blocker = Entry inhibitor = First targeted drug for chronic Hepatitis D

Medical

2026 AHA/ACC Pulmonary Embolism (PE) Classification

sPESI – Pulmonary embolism severity index Mnemonic: COPS BP 100 /80A Cancer, Chronic cardiopulmonary disease, oxygen saturation, pulse rate > 100/min, SBP < 100 mm Hg and Age > 80 years Class Meaning Clinical Features Preferred Initial Anticoagulation Reperfusion Strategy Memory Hack A Asymptomatic PE Incidental PE, no symptoms DOAC or LMWH (Enoxaparin) Not usually required A = Accidental finding B Low-risk symptomatic PE S-PESI = 0   stable DOAC or LMWH (Enoxaparin) None B = breathing comfortably/ Backpack home C Compensated PE Elevated s-PESI but no impending shock LMWH (Enoxaparin); UFH if procedure likely Usually anticoagulation alone C = Careful monitoring D Decompensating PE Normotensive with evidence of impending circulatory collapse (e.g., elevated lactate, AKI, oliguria, altered mental status, low cardiac output) IV Unfractionated Heparin (UFH) PERT evaluation; consider catheter-directed therapy, systemic thrombolysis, or embolectomy D = Deteriorating despite normal blood pressure E Extreme PE Persistent hypotension, obstructive shock, vasopressors, or cardiac arrest IV Unfractionated Heparin (UFH) Immediate systemic thrombolysis if eligible, or catheter thrombectomy/surgical embolectomy E = Emergency   Category C Subclassification Subtype RV Dysfunction Troponin Memory Hack C1 Absent Absent 1 = None positive C2 Present or Absent Absent or Present 2 = One positive C3 Present Present 3 = Two positives High-Yield Anticoagulation Stable (Classes A–C): DOAC or LMWH (Enoxaparin); UFH may be preferred in selected Class C patients if an invasive procedure is anticipated. Unstable (Classes D–E): IV Unfractionated Heparin (UFH) is preferred because it is rapidly reversible and is ideal when thrombolysis, catheter-based intervention, or surgery may be be required.

Medicine

Once-Weekly Insulin Approved in India: A New Era in Diabetes Management

For the first time, once-weekly basal insulin has been approved in India, marking one of the biggest advances in insulin therapy in decades. The approved molecule is Insulin Icodec, a long-acting basal insulin designed to provide 7-day glucose control with a single weekly injection. What is Insulin Icodec? Insulin Icodec is an ultra-long-acting basal insulin analogue developed for adults with diabetes requiring basal insulin therapy. Key Point 1 injection every week Replaces 7 daily basal insulin injections   How Does It Last for 7 Days? Insulin Icodec has been engineered to: Bind strongly to albumin Be released slowly into circulation Maintain stable insulin levels throughout the week This provides a continuous basal insulin effect without major peaks.   Advantages Over Daily Basal Insulin   Only 1 injection per week Better treatment adherence Reduced injection fatigue Similar HbA1c reduction compared with daily basal insulin in clinical trials May improve patient satisfaction and quality of life   Which Patients May Benefit? Once-weekly insulin may be considered for: Type 2 diabetes requiring basal insulin Patients reluctant to start insulin because of daily injections Individuals with poor adherence to daily basal insulin Clinical use should always follow physician guidance and approved prescribing recommendations. Is It for Type 1 Diabetes? Current approval and clinical use primarily focus on adults with Type 2 diabetes requiring basal insulin. Its role in Type 1 diabetes remains more limited and depends on regulatory approvals and clinical guidance. Important Clinical Points It is basal insulin, not mealtime insulin. Rapid-acting insulin is still required when indicated. Weekly dosing requires careful initiation and dose titration. Missing one dose can have a larger impact than missing a single daily basal dose. NEET PG Pearls Feature High-Yield Fact Drug Insulin Icodec Frequency Once weekly Type Ultra-long-acting basal insulin Major Benefit Improves adherence by reducing injections Replaces Daily basal insulin Not Used As Prandial (mealtime) insulin   Memory Trick ICODEC = I COME Once Every Week Remember: Icodec is Once Weekly Basal Insulin   NEET PG/ INICET / FMGE MCQ A newly approved basal insulin in India provides glycemic control with a single injection every week. Which insulin is being described? Insulin Lispro Insulin Glargine Insulin Icodec Insulin Aspart Answer: C. Insulin Icodec Explanation: Insulin Icodec is an ultra-long-acting basal insulin analogue that maintains glucose control for one week, significantly reducing the number of injections required compared with conventional daily basal insulin. Dr Marwah NEET PG Educator for 2 decades generating good, ethical doctors   Links of must watch videos of this channel https://www.youtube.com/watch?v=5reXtUFW-Y0 https://www.youtube.com/watch?v=K-YNyzLENEE https://www.youtube.com/live/houmdnMAmdI

Medical

Early detection of Alzheimer’s disease

Lumipulse G is an FDA-cleared biomarker assay used to aid in the diagnosis of Alzheimer’s disease. The newest version is the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, which is the first FDA-cleared blood test to help detect amyloid pathology associated with Alzheimer’s disease. What does it measure? It measures the ratio of: Phosphorylated tau-217 (pTau217) β-Amyloid 1-42 (Aβ42) This ratio predicts the presence of amyloid plaques in the brain, a pathological hallmark of Alzheimer’s disease. Indications Adults ≥55 years Patients with signs and symptoms of cognitive impairment being evaluated for Alzheimer’s disease. Not intended as a screening test for asymptomatic individuals Advantages Requires only a blood sample. Less invasive than lumbar puncture. Less expensive and more accessible than amyloid PET imaging. Helps determine which patients may benefit from confirmatory testing or anti-amyloid therapies. (U.S. Food and Drug Administration) Interpretation Positive test: Suggests a high likelihood of cerebral amyloid plaques. Negative test: Makes significant amyloid pathology less likely. Does not establish the diagnosis of Alzheimer’s disease by itself; results must be interpreted in conjunction with clinical assessment, neuropsychological testing, and imaging when appropriate. (FDA Access Data) Previous Lumipulse assay An earlier Lumipulse G β-Amyloid Ratio (Aβ42/Aβ40) assay used cerebrospinal fluid (CSF) obtained by lumbar puncture. The newer plasma pTau217/Aβ42 ratio assay is the first FDA-cleared blood-based version. (aafp.org)   Exam pearl for NEET PG and INICET exams Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio ✔ First FDA-cleared blood test for Alzheimer’s disease (2025) ✔ Detects amyloid pathology, not dementia itself ✔ Used in symptomatic patients aged ≥55 years ✔ Cannot replace clinical diagnosis or be used as a standalone screening test     Dr Marwah

Medical

KDIGO 2026 guidelines

Stop memorizing only creatinine and urine output!! KDIGO 2026 introduces damage biomarkers like NGAL, TIMP-2 and IGFBP7, helping detect kidney injury before kidney failure. The future of AKI diagnosis is functional + structural assessment. Master this update now—because the next exam definitely will! #KeepHammering Severity Staging System for AKI Biomarkers of kidney injury: NGAL, TIMP-2 and IGFBP7 These biomarkers indicate G1 cell cycle arrest in Tubular epithelial cells   Why all the hype? These biomarkers can become positive hours before serum creatinine begins to rise, providing an opportunity for earlier recognition and intervention. Functional criteria Structural criteria Serum creatinine Urine output Damage biomarker Stage Criteria Stage Criteria Stage Criteria C0 U0     B1 Positive C1 ≥0.3 mg/dl (≥26.5 μmol/l) increase, Or 1.5-1.9 times baseline U1 <0.5 ml/kg/h for 6-12 hours B0 Negative B1 Positive C2 2-2.9 times baseline U2 <0.5 ml/kg/h for >12 hours B0 Negative B1 Positive   C3 ≥3.0 time baseline, Or Increase in SCr to ≥4.0 mg/dl (≥353.6μmol/l Or Initiation of RRT U3 <0.3 ml/kg/h for 24 hours or anuria for >12 hours B0 Negative B1 Positive 🚨 KDIGO 2026: AKI Diagnosis Has Changed Forever! For years, we have diagnosed Acute Kidney Injury (AKI) using only two functional parameters—serum creatinine and urine output. While these remain the backbone of AKI diagnosis, they have one major limitation: they rise only after significant kidney dysfunction has already occurred. In other words, by the time serum creatinine increases, the kidney may have suffered considerable injury. This is exactly where the KDIGO 2026 guidelines bring a revolutionary change. The new guidelines recognize that kidney injury and kidney dysfunction are not always the same. A patient may already have structural damage to the kidney even though serum creatinine and urine output remain completely normal. Therefore, KDIGO now incorporates damage biomarkers into AKI staging, allowing clinicians to identify injury at a much earlier stage. Functional Criteria – Still the Foundation The functional component remains familiar. Serum Creatinine (C Stage): C1: Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 µmol/L) or 1.5–1.9 times baseline C2: Increase to 2–2.9 times baseline C3: Increase to ≥3 times baseline, serum creatinine ≥4.0 mg/dL, or initiation of renal replacement therapy (RRT) Urine Output (U Stage): U1: Urine output <0.5 mL/kg/hour for 6–12 hours U2: <0.5 mL/kg/hour for more than 12 hours U3: <0.3 mL/kg/hour for 24 hours or anuria for more than 12 hours These criteria continue to define the severity of functional kidney impairment. Structural Criteria – The Game Changer The biggest update is the introduction of structural assessment using damage biomarkers. Examples include: NGAL (Neutrophil Gelatinase-Associated Lipocalin) TIMP-2 (Tissue Inhibitor of Metalloproteinases 2) IGFBP7 (Insulin-like Growth Factor-Binding Protein) These biomarkers can become positive hours before serum creatinine begins to rise, providing an opportunity for earlier recognition and intervention. KDIGO classifies biomarker status as: B0: Biomarker negative B1: Biomarker positive This means a patient may have: Normal creatinine Normal urine output Yet positive biomarkers indicating genuine kidney injury Previously, such patients would have been considered free of AKI. Under KDIGO 2026, they are now recognized as having structural kidney injury, enabling clinicians to intervene before irreversible damage develops. Why Does This Matter? Think of AKI like a myocardial infarction. Years ago, physicians relied on ECG changes alone. Today, troponin detects myocardial injury long before major damage becomes clinically obvious. Similarly, NGAL and Cystatin C act as the “troponins of the kidney,” identifying injury before traditional functional markers deteriorate. Earlier diagnosis means: Prompt correction of hypotension Avoidance of nephrotoxic drugs Better fluid optimization Closer monitoring Potential reduction in progression to severe AKI Exam Pearl For competitive examinations, remember this high-yield concept: KDIGO 2026 = Functional Criteria (Creatinine + Urine Output) + Structural Criteria (Damage Biomarkers). If a future NEET PG, INI-CET, FMGE question asks “Which KDIGO 2026 update is the most important?”, the answer is straightforward: The incorporation of kidney damage biomarkers into AKI staging, allowing detection of structural kidney injury even before serum creatinine rises. This is one of the most important nephrology updates in recent years—and a topic every exam aspirant should master. Keep Hammering! 💙 Dr Marwah

Medicine, Medicine classes

Must know Target BP values in neuro-emergencies

This is a must know topic that is asked in UPSC CMS, NEET PG and INICET examinations. Go through this mini blog with approximate read time of 3 minutes and remember each line. Condition Target Remarks SAH SBP < 140-160 For raised ICP: Keep CPP > 60 Prevent re-bleeding while maintaining cerebral perfusion. Spontaneous ICH SBP -140/90 Reduces hematoma expansion Acute Ischemic Stroke (Thrombolysis Candidate) Pre-lysis: SBP < 185, DBP < 110 Post-lysis (24h): SBP < 180, DBP < 105 Reduces risk of ICH due to Thrombolytics Acute ischemic Stroke (No Thrombolysis) If SBP > 220 or DBP > 120 ↓BP by -15% in 24h Permissive HTN supports penumbra perfusion. Avoid rapid/larger drops.   Hypertensive Encephalopathy ↓ MAP by 20-25% in 1st hour, then gradual Symptoms improve with controlled reduction. Traumatic Brain Injury SBP 100  CPP 60-70 Keep CPP > 60 mmm Hg if ICP monitor available Aortic Dissection HR < 60 bpm  SBP 100-120 Reduce shear stress. Treat pain/anxiety first. First-line: β-blockers (Labetalol, Esmolol), First-line agents (neuro HTN): Nicardipine and Labetalol Avoid: Nitroprusside, Nitroglycerin NTG may be required if pulmonary edema present due to cardiac comorbidity and needs individual Now attempt an MCQ to test your knowledge For more such interesting topics keep visiting this website run by Dr Marwah who is a national level faculty for NEET PG and INICET examination.

Medicine, NEET PG, NExT, NExT Exam

The Future of Anti-Hypertensive Therapy Explained

Once in 6 Months Blood Pressure Injection: The Future of Anti-Hypertensive Therapy Explained High blood pressure affects millions of people in India — and nearly 1 in 4 adults lives with hypertension, many without knowing it. The real challenge is not just treatment, but taking medicines regularly. Now imagine controlling blood pressure with just two injections per year. A new investigational therapy called zilebesiran may make this possible. Let’s understand it in simple language — clinically relevant, exam-focused, and easy to remember.   Featured Snippet: What Is the Once-in-6-Months Blood Pressure Injection? The once-in-6-months blood pressure injection refers to zilebesiran, an investigational RNA-interference therapy that lowers blood pressure by reducing liver production of angiotensinogen, a key component of the RAAS pathway. A single subcutaneous injection may provide blood pressure control for up to 6 months. 🇮🇳 Why This Matters: Hypertension in India Around 25–30% of Indian adults have hypertension. Many remain undiagnosed or irregular with treatment. Poor medication adherence leads to stroke, heart failure, and kidney disease. This makes long-acting therapies extremely interesting for the future of cardiovascular care. Related reading: [Hypertension management guide] (internal link)   Really? A Once-in-6-Months Anti-Hypertensive Drug? Yes — and this is what makes zilebesiran unique. Unlike conventional drugs that block hormones after formation, this drug works at the gene expression level. Daily pills block RAAS… RNAi stops RAAS from being born.   Mechanism of Action of Zilebesiran Target Liver-produced angiotensinogen (AGT) Method RNA interference (gene silencing) Effect ↓ Angiotensinogen ↓ Angiotensin II formation ↓ Vasoconstriction ↓ Blood pressure This means the drug acts upstream in the RAAS pathway, creating prolonged suppression. Related reading: [RAAS system explained simply] (internal link) Why Only Twice a Year? RNA-interference molecules remain active inside cells for a long time. Because of prolonged intracellular action: One subcutaneous injection suppresses AGT production for ~6 months. Dosing becomes biannual instead of daily. This mirrors what happened in diabetes care when therapy shifted from daily insulin to weekly injections. Clinical Trial Evidence — KARDIA Trials Phase II Study Highlights Double-blind, placebo-controlled trial 672 patients with hypertension Average baseline SBP: 143 mm Hg Key Findings Significant reduction in systolic BP vs placebo Additional benefit on top of standard medications BP lowering sustained for up to 6 months after one dose In some studies, the effect was similar to adding another oral antihypertensive drug. Why Is This a Big Deal? Solves adherence problems: Many patients forget daily pills. Twice-yearly injections could transform compliance. Continuous blood pressure control: No missed doses means more stable BP. Potential use in high-risk patients: Especially those uncontrolled despite multiple medications.   Limitations (Important Clinical Perspective) Still investigational (not routine therapy yet) Long duration means limited dose adjustment Side effects, if any, may persist longer Expected to be costlier initially So no — this does NOT replace current BP medicines yet.   Frequently Asked Questions (FAQ) ❓ What is the once-in-6-months BP injection? It is zilebesiran, an investigational RNA-interference drug that lowers blood pressure by reducing angiotensinogen production in the liver. Is zilebesiran available in India? No. It is currently under clinical trials and not yet approved for routine use. How does it differ from ACE inhibitors or ARBs? ACE inhibitors block hormone action, whereas zilebesiran prevents hormone production upstream. Who may benefit in the future? Patients with poor medication compliance or resistant hypertension may benefit if approved. Is it better than regular tablets? Not necessarily — current drugs remain effective and affordable.   Quick Summary Box Feature Zilebesiran Type RNA interference therapy Target Hepatic angiotensinogen Route Subcutaneous injection Frequency Every 6 months Status Investigational (Phase III underway) Major Advantage Improved adherence   Conclusion Will this replace daily BP tablets? Not yet. But it may represent the next evolution of hypertension treatment — where technology helps solve the biggest real-world problem: patients forgetting medicines. The future of cardiovascular pharmacology is moving toward long-acting, precision-based therapies — and zilebesiran may be one of the first steps in that direction.   References World Health Organization (WHO) ICMR Hypertension Data American College of Cardiology (ACC) trial presentations  

Medical

NEET PG vs INICET: Same Syllabus, Two Worlds Apart!”

Think NEET PG and INI-CET prep is the same just because the syllabus overlaps? Think Again. One exam throws you a straightforward question like, “Drug treatment for malaria on Day 2 with dosages?” The other presents a 6 line clinical stem with an image of a Giemsa stain and has multiple correct options. The examiners expect you to tell placenta accreta by looking at placenta to evaluate homer wright vs flexner wintersteiner rossetes.   INI-CET is the battleground for the thinkers, the pattern recognizers, the fast processors NEET PG rewards the image interpreters, the masters of repeat questions and factual clarity. So, how do you prepare differently for each? Which subjects should you double down on for AIIMS -style integrated shocks, and where should you focus for NEET’s smart scoring? This guide breaks it all down – from question styles and traps to subject – wise smart prep. Whether you’re aiming for the top rank in INI-CET or looking to crush NEET PG with speed and precision, this article will completely change the way you approach both exams. These two are the golden ticket to your financial freedom. It takes a lot of guts to persist for 5.5 years in medical collage. Now you need to up the game further and handle things better. INI-CET vs NEET PG: MCQ Pattern & Subject Focus Featured INI-CET NEET PG  Question pattern Conceptual, clinical, integrated and image-heavy Conceptual + Factual mix, with clinical vignettes Difficulty level High Moderate to high Image -Based questions 15-20% 25% -30% Integrated Questions Very common (across 2-3 subjects in one stem) Increasing trend, but less intense One – liners Super tricky and sticky ones Moderate number, especially in Biochemistry, Pharmacology, Microbiology Repeat questions Heavy on new formats of same concept example hypercalcemic crisis but asked in different scenarios Less frequent repeats Length of Questions Often lengthy clinical vignettes Moderate length; easier to read quickly Time pressure High – as time per Q is less, requires rapid thinking Moderate – balanced speed vs accuracy needed Numerical Qs/ Image Qs Lab values, CTs, X-rays, staining ECGs X-rays, CTs, derm images Negative Marking Yes Yes Number of Questions 200 Qs in 3 hrs 200 Qs in 3.5 hrs   Quick glance at subject -wise Focus: INI-CET vs NEET PG Subject INI-CET Focus Areas NEET PG Focus Areas Medicine Clinical case integration, rare diseases, ECGs, X-rays, neurology, rheumatology High-yield cases (MI, stroke, infections), guidelines- based management Surgery Recent updates (e.g, Hernia types), instruments, surgical anatomy Trauma, acute abdomen, hernia, wound healing Obs-Gynae Instrument ID, CTSs, syndromes, new protocols Labor stages, PPH, contraception, GTD Pediatrics Syndromes, growth charts, milestone charts, genetic diseases IMNCI, nutrition, vaccines, common infections Pathology Integrated with medicine (e.g. SLE histo + lab) Classic one-lines + integrated Qs Pharmacology New drugs, mechanisms, adverse effects in clinical setting Repeats: DOCs, side effects, antidotes Microbiology Lab diagnosis, integration with cases, images (stains, cultures) Organism + disease pairings, vaccines Biochemistry Enzyme defects, clinical case application Classical one – liners (e.g. glycogen storage diseases) Anatomy CT/MRI -based Qs, Neuroanatomy, embryo integration Brachial plexus, cranial nerves, surface anatomy Physiology CVS, neurophysiology, respiratory case scenarios Graphs ( lung volumes, action potential), easy recall Qs PSM Biostats, scoring systems, integrated screening guidelines Repeats: OR, RR, NHPs, vaccine schedules Short subjects Psychiatry, dermatology, radiology, anesthesia – often in image form High repeat value; direct and easy to score AIIMS signature areas Optics (ophthal), ENT instruments, NEET SS- style integrations Less common

Medical

Cytotoxic vs Vasogenic Cerebral Edema – key Differences

Questions on types of cerebral oedema are frequent in NEET PG, INI-CET, and FMGE exams—often integrated in clinical scenarios involving trauma, stroke, tumors, or infections. Differentiating vasogenic vs cytotoxic edema is not just academic—it’s clinically relevant, radiologically distinct, and high-yield for MCQs. Feature Cytotoxic Edema Think neuronal Cell is swollen Vasogenic Edema Think Vascular leak   Etiology Ischemia, hypoxia, seizures Tumors, infections, trauma   Pathophysiology Failure of Na⁺/K⁺ ATPase due to hypoxia → intracellular sodium and water accumulation Disruption of the blood-brain barrier (BBB) → leakage of plasma and proteins into the extracellular space   Fluid Location Intracellular (inside neurons/ glia) Extracellular (interstitial space)   Imaging (DWI) Restricted diffusion (DWI bright, ADC dark) No true restriction (DWI May be normal or Mildly bright, ADC high)   Location Affects grey + white matter Affects white matter only, spares cortex   Response to steroids No benefit Responsive to steroids (e.g. peritumoral edema)   NCCT head Notice loss of gray and white matter differentiation Notice the finger like projection appearance due to exclusive white matter differentiation   Image credits and source: Radiopedia.com In a competitive exam like NEET PG, where every question matters, mastering the pathophysiology, imaging, and treatment implications of cerebral oedema can be the difference between a top rank and an average one.  

Scroll to Top